Abstract
Objective
Preclinical investigations have established that methamphetamine (MA) produces long-term changes in dopamine (DA) neurons in the striatum. Human studies have suggested similar effects and correlated motor and cognitive deficits. The present study was designed to further our understanding of changes in brain function in humans that might result from chronic high dose use of MA after at least 3 months of abstinence.
Method
Brain function in abstinent users was compared to controls using neuroimaging of monoamine transporters and cognitive assessment. Striatal levels of DA transporter (DAT) and vesicular monoamine transporter type-2 (VMAT2) were determined using [11C]methylphenidate and [11C]dihydrotetrabenazine positron emission tomography, respectively. Cognitive function was evaluated using tests of motor function, memory, learning, attention, and executive function.
Results
Striatal DAT was approximately 15% lower and VMAT2 was 10% lower in MA abusers across striatal subregions. The MA abusers performed within the normal range but performed more poorly compared to controls on three of the 12 tasks.
Conclusions
Failure to find more substantial changes in transporter levels and neurocognitive function may be attributed to the length of time that MA users were abstinent (ranging from 3 months to more than 10 years, mean 3 years), although there were no correlations with length of abstinence. Persistent VMAT2 reductions support the animal literature indicating a toxic effect of MA on nigrostriatal nerve terminals. However, the magnitude of the MA effects on nigrostriatal projection integrity is sufficiently small that it is questionable whether clinical signs of DA deficiency are likely to develop.
Similar content being viewed by others
References
Ando K, Johanson CE, Schuster CR (1986) Effects of dopaminergic agents on eye tracking before and after repeated methamphetamine. Pharmacol Biochem Behav 24:693–699
Biederman J, Wilens T, Mick E, Milberger S, Spencer T, Faraone S (1995) Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 152:1652–1658
Bohnen NI, Albin RL, Koeppe RA, Wernette K, Kilbourn MR, Minoshima S, Frey KA (1996) Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab. DOI 10.1038/sj.jcbfm.9600276
Chang L, Ernst T, Speck O, Patel H, DeSilva M, Leonido-Yee M, Miller EN (2002) Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users. Psychiatry Res 114:65–79
Delis D, Kramer J, Kaplan E, Ober B (1987) The California verbal learning test. Psychological Corporation
Ernst T, Chang L, Leonido-Yee M, Speck O (2000) Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study. Neurology 54:1344–1349
First MB, Spitzer RL, Gibbon M, Williams JBW (1996) Structured clinical interview of DSM-IV axis I disorders—patient edition (SCID I/P), version 2. Biometrics Research Dept., NY State Psychiatric Institute
Frey K, Kilbourn M, Robinson T (1997) Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur J Pharmacol 334:273–279
Harvey DC, Lacan G, Tanious SP, Melega WP (2000) Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Res 871:259–270
Hotchkiss AJ, Gibb JW (1980) Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J Pharmacol Exp Ther 214:257–262
Johanson CE, Aigner TG, Seiden LS, Schuster CR (1979) The effects of methamphetamine on fine motor control in rhesus monkeys. Pharmacol Biochem Behav 11:273–278
Kalechstein AD, Newton TF, Green M (2003) Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J Neuropsychiatry Clin Neurosci 15:215–220
Klove J (1964) Clinical neuropsychology. Saunders, New York
Koeppe RA, Frey KA, Kume A, Albin R, Kilbourn MR, Kuhl DE (1997) Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)-alpha-[11C]dihydrotetrabenazine (DTBZ) and positron emission tomography. J Cereb Blood Flow Metab 17:919–931
Koeppe RA, Frey KA, Kuhl DE, Kilbourn MR (1999) Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine. J Cereb Blood Flow Metab 19:1376–1384
Lew R, Malberg J (1997) Evidence for and mechanism of action of neurotoxicity of amphetamine related compounds. In: Kostrzewa R (ed) Highly selective neurotoxins: basic and clinical applications. Humana, Totowa, NJ, pp 235–268
Lorez H (1981) Fluorescence histochemistry indicates damage of striatal dopamine nerve terminals in rats after multiple doses of methamphetamine. Life Sci 28:911–916
McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA (1998) Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 18:8417–8422
Moszczynska A, Fitzmaurice P, Ang L, Kalasinsky KS, Schmunk GA, Peretti FJ, Aiken SS, Wickham DJ, Kish SJ (2004) Why is parkinsonism not a feature of human methamphetamine users? Brain 127:363–370
Nordahl TE, Salo R, Possin K, Gibson DR, Flynn N, Leamon M, Galloway GP, Pfefferbaum A, Spielman DM, Adalsteinsson E, Sullivan EV (2002) Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: a preliminary proton MRS study. Magnetic resonance spectroscopy. Psychiatry Res 116:43–52
Ornstein TJ, Iddon JL, Baldacchino AM, Sahakian BJ, London M, Everitt BJ, Robbins TW (2000) Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology 23:113–126
Reitan R (1958) Validity of the trail making test as an indication of organic brain damage. Percept Mot Skills 8:271–276
Reitan R (1969) Manual for administration of neuropsychological test batteries for adults and children. Indianapolis
Ricaurte GA, Guillery RW, Seiden LS, Schuster CR, Moore RY (1982) Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res 235:93–103
Ringe W, Saine K, Lacritz L, Hynan L, Cullum C (2002) Dyadic short forms of the Wechsler intelligence scale III. Assessment 9:254–260
Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt P (1994) Cambridge neuropsychological test automated battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia 5:266–281
Robbins TW, James M, Owen AM, Sahakian BJ, Lawrence AD, McInnes L, Rabbitt PM (1998) A study of performance on tests from the CANTAB battery sensitive to frontal lobe dysfunction in a large sample of normal volunteers: implications for theories of executive functioning and cognitive aging. Cambridge neuropsychological test automated battery. J Int Neuropsychol Soc 4:474–490
Salo R, Nordahl TE, Possin K, Leamon M, Gibson DR, Galloway GP, Flynn NM, Henik A, Pfefferbaum A, Sullivan EV (2002) Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals. Psychiatry Res 111:65–74
Sattler J, Ryan J (2001) Tables for WAIS-III. In: Sattler J (ed) Assessment of children: cognitive applications. Jerome M. Sattle, San Diego, CA, pp 812–835
Seiden LS, Ricaurte G (1987) Neurotoxicity of methamphetamine and related drugs. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven, New York, pp 359–366
Seiden LS, Fischman MW, Schuster CR (1976) Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend 1:215–219
Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Takei N, Mori N (2001) Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158:1206–1214
Sekine Y, Minabe Y, Ouchi Y, Takei N, Iyo M, Nakamura K, Suzuki K, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Mori N (2003) Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry 160:1699–1701
Simon SL, Domier C, Carnell J, Brethen P, Rawson R, Ling W (2000) Cognitive impairment in individuals currently using methamphetamine. Am J Addict 9:222–231
Simon SL, Domier CP, Sim T, Richardson K, Rawson RA, Ling W (2002) Cognitive performance of current methamphetamine and cocaine abusers. J Addict Dis 21:61–74
Sossi V, Holden J, Chan G, Krzywinski M, Stoessl A, Ruth T (2000) Analysis of four dopaminergic tracers kinetics using two different tissue input function methods. J Cereb Blood Flow Metab 20:653–660
Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y, Lee JY, Toga AW, Ling W, London ED (2004) Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 24:6028–6036
Vander Borght TM, Sima AAF, Kilbourn MR, Desmond TJ, Kuhl DE, Frey KA (1995a) [3H]Methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience 68:962–995
Vander Borght TM, Kilbourn MR, Desmond TJ, Kuhl DE, Frey KA (1995b) The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 294:577–583
Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley SJ, Schlyer DJ, Pappas N (1995) A new PET ligand for the dopamine transporter: studies in the human brain. J Nucl Med 36:2162–2168
Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, Gatley SJ, Miller E, Hitzemann R, Ding YS, Logan J (2001a) Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 21:9414–9418
Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding YS, Logan J, Wong C, Miller EN (2001b) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158:377–382
Wagner GC, Ricaurte GA, Seiden LS, Schuster CR, Miller RJ, Westley J (1980) Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res 181:151–160
Wechsler D (1997) Wechsler adult intelligence scale—administration and scoring manual, 3rd edn. Psychological Corporation
Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2:699–703
Zachary R (1986) Manual for the revised Shipley institute of living scale. Western Psychological Services
Acknowledgements
This research was supported by Joe Young, Sr funds from the State of Michigan, grants from NIDA (DA12458 to CRS, DA14392 to JR, and R01 DA10641 to GPG), NCRR (RR00042 to KF), and NINDS (NS15655 to KF). PK is presently employed in the medical affair division of Ortho-McNeill/Janssen. TWR consults for Cambridge Cognition. The authors wish to thank staff from Wayne State University (staff of the Neuropsychiatric Research Unit: Ken Bates for recruitment; Ja’Near Mathis for urine analyses; and Cheryl Aubie, Kelty Berardi, and Jennifer Raiter for psychiatric diagnoses, neurocognitive assessments, and data management) and staff from the University of Michigan PET Center.
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article can be found at http://dx.doi.org/10.1007/s00213-006-0393-4
Rights and permissions
About this article
Cite this article
Johanson, CE., Frey, K.A., Lundahl, L.H. et al. Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology 185, 327–338 (2006). https://doi.org/10.1007/s00213-006-0330-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-006-0330-6